New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
16:41 EDTVVUSVIVUS reports Q4 EPS (56c), consensus (44c)
Reports Q4 revenue $1.97M, consensus $3.09M. The increase in net loss was primarily attributable to higher selling, general and administrative expenses related to commercialization activities for Qsymia. In Q4, the company recognized net product revenues of $2M from sales of Qsymia.
News For VVUS From The Last 14 Days
Check below for free stories on VVUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
07:03 EDTVVUSVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use